BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9180292)

  • 1. The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
    Asschert J; de Vries E; van der Kolk D; Müller M; Vellenga E
    Leukemia; 1997 May; 11(5):680-6. PubMed ID: 9180292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
    van der Graaf WT; de Vries EG; Timmer-Bosscha H; Meersma GJ; Mesander G; Vellenga E; Mulder NH
    Cancer Res; 1994 Oct; 54(20):5368-73. PubMed ID: 7923167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
    den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
    Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
    Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.
    Seidel A; Hasmann M; Löser R; Bunge A; Schaefer B; Herzig I; Steidtmann K; Dietel M
    Virchows Arch; 1995; 426(3):249-56. PubMed ID: 7773504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
    Toffoli G; Simone F; Gigante M; Boiocchi M
    Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic triptycene bisquinone, which blocks nucleoside transport and induces DNA fragmentation, retains its cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines.
    Wang B; Wu M; Perchellet EM; McIlvain CJ; Sperfslage BJ; Huang X; Tamura M; Stephany HA; Hua DH; Perchellet JP
    Int J Oncol; 2001 Dec; 19(6):1169-78. PubMed ID: 11713586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia.
    Grey MR; Burgess R; Fisher A; Yin JA
    Leuk Res; 1999 Jan; 23(1):29-35. PubMed ID: 9933132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
    Goulding CW; Giuliano AE; Cabot MC
    Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and modulation of drug transport kinetics in K562 c1.6 daunorubicin-resistant cell line.
    Jiang XR; Macey MG; Collins PW; Newland AC
    Br J Haematol; 1994 Mar; 86(3):547-54. PubMed ID: 8043436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
    Lage H; Dietel M
    J Cancer Res Clin Oncol; 2002 Jul; 128(7):349-57. PubMed ID: 12136248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
    Stahl M; Kasimir-Bauer S; Harstrick A
    Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
    Boesch D; Muller K; Pourtier-Manzanedo A; Loor F
    Exp Cell Res; 1991 Sep; 196(1):26-32. PubMed ID: 1879470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantrone in multidrug-resistant K562 cells.
    Fukushima T; Yamashita T; Takemura H; Suto H; Kishi S; Urasaki Y; Ueda T
    Leuk Res; 2000 Mar; 24(3):249-54. PubMed ID: 10739007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
    Volk EL; Rohde K; Rhee M; McGuire JJ; Doyle LA; Ross DD; Schneider E
    Cancer Res; 2000 Jul; 60(13):3514-21. PubMed ID: 10910063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.